Please assess the completion status of the following clinical trial:

Trial Title: Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes can and will comply with the requirements of the protocol.~* A male or female between, and including, 18 and 45 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Have clinically normal laboratory values for creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), complete blood count (CBC) and differential at screening.~* Be seronegative for human immunodeficiency virus-1 and 2 (HIV 1/2) antibodies, HBsAg and hepatitis C virus (HCV) antibodies.~* Have anti HBs titre ≥ 10mIU/ml at screening.~* If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Any history of clinical malaria.~* Known exposure to malaria parasites within the previous 12 months.~* Planned travel to a malaria endemic region during the study period.~* History of allergic reactions or anaphylaxis to previous immunizations.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Personal history of autoimmune disease or subjects who describe a first-degree relative with clearly documented autoimmune disease.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).~* Major congenital defects or serious chronic illness(es).~* Acute disease at the time of enrolment.~* History of any neurologic disorders or seizures.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Hepatomegaly, right upper quadrant abdominal pain or tenderness.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* History of previous exposure to experimental products containing any component of the vaccines used in this study.~* Pregnant or lactating female.~* History of chronic alcohol consumption and/or drug abuse.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: EXPERIMENTAL): None
- Group C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete